Current Oncology Reports
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies
Current Oncology Reports - Tập 25 - Trang 569-587 - 2023
Patients seek clinical guidance on mushroom
supplements that can be given alongside conventional treatments, but most research on such fungi has been preclinical. The current systematic review focused on clinical studies of mushrooms in cancer care conducted in the past 10 years. We searched Medline (Ovid), Embase (Ovid), Scopus (Wiley), and Cochrane Library to identify all mushroom studies condu......
The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion
Current Oncology Reports - Tập 15 - Trang 207-216 - 2013
Malignant pleural effusions (MPEs) are a significant source of cancer-related morbidity. Over 150,000 patients in the United States suffer from breathlessness and diminished quality of life due to MPE each year. Current management strategies are of mostly palliative value and focus on symptom control; they do not address the pathobiology of the effusion, nor do they improve survival. Further eluci......
When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab
Current Oncology Reports - Tập 21 - Trang 1-8 - 2019
One year of trastuzumab dramatically improves outcomes in early HER2 positive breast cancer, irrespective of anatomic stage, receptor status and chemotherapy backbone. However, up to 25% of breast cancers treated with trastuzumab and chemotherapy recur. Here, we review the current role for additional HER2 blockade to adjuvant trastuzumab. Adjuvant pertuzumab and neratinib modestly improve disease-......
Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors
Current Oncology Reports - Tập 11 - Trang 322-328 - 2009
Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas that rarely occur in the general population but have a lifetime incidence of 8% to 13% in those with neurofibromatosis type 1 (NF1). Complete surgical resection is the standard treatment for MPNSTs. Unresectable MPNSTs carry a poor prognosis, and survival appears to be worse in NF1-associated tumors than i......
The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery
Current Oncology Reports - Tập 19 - Trang 1-6 - 2017
The American Society of Clinical Oncology (ASCO) palliative care recommendations have been updated into a full guideline. Symptom questionnaires—completed and reviewed with patients during care delivery—are poised to play a large role in this guideline because they provide a more comprehensive understanding of symptoms. This article provides an overview of the guideline and describes how symptom q......
Second Primary Tumors in Patients with Head and Neck Cancer
Current Oncology Reports - Tập 13 - Trang 132-137 - 2011
This is a review on second primary tumors in patients with head and neck cancer. These patients have a high risk of developing other cancers simultaneously or subsequently. The incidence of multiple primary tumors in this population can be as high as 27%. Recurrences are the most common cause of treatment failure within the first 2 years of follow-up. After the third year the diagnosis of a second......
Risk assessment models to estimate cancer probabilities
Current Oncology Reports - Tập 9 - Trang 503-508 - 2008
Cancer risk has become a significant research topic due to an increase in statistical risk models built to predict cancer incidence or mortality. Over the past 3 years, 15 models on the development of different types of cancer, including breast, colorectal, prostate, gastric, lung, ovarian, pancreatic, testicular, and skin, have been published. Risk assessment models are dynamic; they need to be u......
Targeting KRAS in Colorectal Cancer
Current Oncology Reports - Tập 23 - Trang 1-10 - 2021
Mutations in kirsten rat sarcoma viral oncogene homolog (KRAS) are the most frequently observed genomic alterations in human cancers. No KRAS targeting therapy has been approved despite more than three decades of efforts. Encouraging progress has been made in targeting KRASG12C with KRASG12C specific covalent inhibitors in the past few years. Herein, we review the recent breakthroughs in KRAS targ......
Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan
Current Oncology Reports - - Trang 1-9 - 2023
HER2-positive breast cancer accounts for 10–15% of all breast cancers and fam-trastuzumab deruxtecan (T-DXd) has played a major role in moving the treatment of HER2-expressing disease forward. T-DXd is a novel antibody–drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody against HER2 receptor bound to a potent topoisomerase I cytotoxin payload by a cleavable peptide linker. It has......
New Targets in Non-Small Cell Lung Cancer
Current Oncology Reports - Tập 15 - Trang 411-423 - 2013
Lung cancer remains the most common cause of cancer-related death in the United States. At presentation, the majority of patients have regional or systemic metastases and therefore require systemic therapy. For years, chemotherapy was the only systemic therapy option. A major paradigm shift has occurred in recent years with the identification of driver genetic alterations in some non-small cell lu......
Tổng số: 1,491
- 1
- 2
- 3
- 4
- 5
- 6
- 10